.svg){kind=small}
Jun-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In June 2026, Stigma Grow’s mix concentrated into two categories: Concentrates expanded to 66.34% share with year-over-year growth of 30.18% and month-over-month growth of 0.94%, while Capsules contracted to 31.90% share with a year-over-year decline of 56.41% and a month-over-month drop of 27.84%; Flower remained marginal at 1.76% share with year-over-year decline of 45.53% and month-over-month decline of 21.41%. Despite brand-level sales down 21.59% year over year and average price down 1.49%, the tilt toward Concentrates coincides with an Alberta Concentrates rank of 8, implying the brand is consolidating around a comparatively steadier channel where share and ranking can buffer volatility from collapsing Capsules.
The shift implies Stigma Grow is trading depth for breadth: by leaning into Concentrates at 66.34% share and posting 30.18% year-over-year growth there while allowing Capsules to decline 56.41% year over year to 31.90% share, the brand is concentrating demand where pricing at $31.98 is close to the brand average of $32.17. With month-over-month movement of +0.94% in Concentrates versus −27.84% in Capsules and an Alberta Concentrates rank of 8, the pattern suggests prioritizing a defendable niche to stabilize ranks and recover share, even at the cost of overall top-line contraction and reduced category diversification.
Competitive Landscape
Stigma Grow ranks #8 in AB Concentrates in June 2026, improving 11 positions year over year from #19 while gaining 3 spots since March 2026 when it was #11; this new #8 also matches its peak rank to date in June 2026. Against the leaders, BoxHot moved from #2 to #1 with 37.9% YoY sales growth while Endgame slipped from #1 to #2 with a 23.4% YoY sales decline, indicating Stigma Grow’s upward rank shift is occurring amid both expansion at the top and contraction among prior leaders. The pattern implies Stigma Grow’s trajectory is momentum-driven and opportunistic: share gains are being converted into rank improvements as incumbents shuffle, positioning the brand to challenge the #5–#7 tier if the 3-rank advance since March 2026 persists.
Notable Products
Phoenix Tears Honey Oil (1g) delivered the standout jump at +88.7% month over month to rank 5 in June 2026, while Indica RSO Capsules 25-Pack (250mg) fell -26.6% to rank 2 and CBD Softgels 15-Pack (750mg CBD) dropped -42.0% at rank 3. Concentrates held 6 of the top 10 positions including ranks 1, 4, 5, 6, and 7, with Phoenix Tears RSO (1g) easing -2.1% but retaining rank 1, which implies a pivot toward extract-led volume even as capsules contract.
Grape Limeade (14g) declined -75.3% to rank 9, while Twisted Citrus (14g) rose +23.4% to rank 8, concentrating Flower performance at lower ranks and below the extract cluster. With Phoenix Tears RSO (1g) still the revenue anchor at $110,616 and Phoenix Tears Honey Oil (1g) surging, the pattern points to Stigma Grow leaning into Phoenix Tears-branded concentrates as the commercial priority over June 2026.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
